These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2618884)

  • 21. [Continuous subcutaneous infusion of peplomycin for advanced prostatic cancer patients].
    Satake I; Tari K
    Hinyokika Kiyo; 1985 May; 31(5):875-83. PubMed ID: 2413747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
    Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ
    Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
    Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
    J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
    Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
    Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
    Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
    Hervonen P; Lehtinen T; Tammela TL; Kellokumpu-Lehtinen P
    J Exp Clin Cancer Res; 2002 Jun; 21(2):177-80. PubMed ID: 12148574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma].
    Kattan J; Droz JP; Culine S
    Bull Cancer; 1993 Mar; 80(3):248-54. PubMed ID: 8173177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ifosfamide in combined hormonochemotherapy on prostate cancer].
    Fujita K; Matsushima H; Nakano M; Kaneko T
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):227-30. PubMed ID: 8311493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Radiation recall dermatitis after oral cyclophosphamide].
    Mievis C; Jansen N; Schleich F; Gennigens C; Rorive A; Jérusalem G; Fillet G; Sautois B
    Rev Med Liege; 2009 Apr; 64(4):179-81. PubMed ID: 19514535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer.
    Brandes LJ; Bracken SP; Ramsey EW
    J Clin Oncol; 1995 Jun; 13(6):1398-403. PubMed ID: 7751884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Estrogen-resistant prostatic cancer with bone metastases: palliative chemotherapy with 5-fluorouracil and cyclophosphamide].
    Küss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP
    Nouv Presse Med; 1978 Aug 26-Sep 2; 7(28):2478-9. PubMed ID: 80785
    [No Abstract]   [Full Text] [Related]  

  • 37. Chemotherapy of metastatic prostate adenocarcinomas in germfree rats. I. Effects of cyclophosphamide (NSC-26271).
    Pollard M; Luckert PH
    Cancer Treat Rep; 1976 May; 60(5):619-21. PubMed ID: 991152
    [No Abstract]   [Full Text] [Related]  

  • 38. [Severe acute thrombosis induced by high dosage of estrogen therapy].
    Danis RK; Lasry G; Melliere D; Beaumont V; Botto H
    Nouv Presse Med; 1978 Jul 1-8; 7(27):2396. PubMed ID: 673816
    [No Abstract]   [Full Text] [Related]  

  • 39. Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
    Schmidt JD; Gibbons RP; Johnson DE; Prout GR; Scott WW; Murphy GP
    Urology; 1976 Jun; 7(6):602-10. PubMed ID: 936381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of adenocarcinoma of prostate with diethylstilbestrol diphosphate and cyclophosphamide.
    Sinclair GR; Lupu AN; de Kernion JB
    Urology; 1975 May; 5(5):665-8. PubMed ID: 48303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.